Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Soleno Therapeutics shares surge on positive patent news

The firm has received a new patent (9,757,384) from the relevant US office, it said in a statement
Soleno Therapeutics shares surge on positive patent news
The firm is developing a Diazoxide Choline Controlled Release Tablet (DCCR), it said

Soleno Therapeutics Inc (NASDAQ:SLNOW) shares added almost 50% in New York as the biopharma group issued positive patent news.

The firm has received a new patent (9,757,384) from the relevant US office, related to the use of certain pharmaceutical formulations to reduce one or more aggressive behaviours in a patient with genetics disorders Prader-Willi syndrome (PWS) or Smith-Magenis syndrome (SMS).

The firm is developing a Diazoxide Choline Controlled Release Tablet (DCCR).

“This patent will further strengthen the intellectual property portfolio for DCCR, our lead product candidate, for the treatment of PWS,” said Anish Bhatnagar, Soleno Therapeutics' chief executive in a statement today.

"Importantly, this most recent patent will provide protection of associated claims into 2035. We expect to leverage additional intellectual property opportunities for DCCR over the coming months.”

Soleno expects to begin a Phase III clinical trial of DCCR in Prader-Willi syndrome (PWS) by the end of 2017.

It is now finalising the design of a randomized, double-blind placebo-controlled study to treat around 100 patients.

This study is expected to take around nine to 12 months to complete. DCCR has orphan drug status for the treatment of PWS in the USA.

View full SLNOW profile View Profile

Related Articles

PreveCeutical Medical bidding to be big player in preventive healthcare
October 10 2017
Van Deventer aims to grow the firm's valuation from its current $40mln market cap to $1bn plus in the next few years
The Hydroponics Company Ltd issued a cannabis research licence
July 11 2017
The licence allows Canndeo to build its exclusive Plant Breeders Rights.
Regeneus: Access latest PPT from Proactive's CEO Sessions
June 18 2017
John Martin discussed regenerative medicine with investors.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use